A knowledge of the concentration of a drug in blood or other tissue fluid is now considered an important and sometimes essential part of the therapeutic management of various conditions. Its importance has increased as information showing wide interindividual variation in drug response has become recognised. Such variation arising from differences in absorption, distribution, and elimination appears to be greater during development, and yet many drugs are still prescribed for children in doses calculated by scaling down adult doses according to weight or surface area. 1 This conventional dose approach is satisfactory only for drugs with a large therapeutic index (the difference between therapeutic and toxic drug levels is wide). Doses of most drugs need to be individually tailored according to the child's particular requirements. Titration of dose to the therapeutic response is the best means of achieving this. However, this approach is unsuitable for most of the commonly prescribed drugs in children (antimicrobials, anticonvulsants, anti-inflammatory agents, cardiac glycosides) as the response to these is not readily clinically evaluated, and there may be a subtherapeutic or toxic response. As a result, drugs may be discarded as useless or too toxic.
For many drugs, there is a close relationship between plasma level and therapeutic effect, and the value of knowing the plasma level has been proved for a number of drugs (Table 1) . Although fewer data are available for these drugs in children, in the case of most drugs the plasma level-therapeutic response relationship will be better than that between dosage and clinical effectiveness. However, it should be remembered that the represented by a two-compartment110 or even a multicompartment model.11' The authors proposing the latter model suggested that treatment should be tailored individually for children, based on peak and trough levels after the fourth or fifth dose, which would still be fairly early in the course of treatment.
Tobramycin. Information on desirable drug levels of tobramycin is limited. McAllister and Tait1"2 stated that the 'usual' dose given to adults produces serum levels of 11-21 ,umol/l, and it has therefore been suggested that organisms with MICs <11 ,umol/l should be considered sensitive to tobramycin.113 According to a commercial report,"4 sustained levels above 26 ,umol/l are likely to produce adverse effects and should be avoided. Although the incidence of both nephro-and ototoxicity may be marginally less with tobramycin than with gentamicin,"5 and there is little documentary evidence of a relationship between toxicity and drug level, a therapeutic plasma range of [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] ,umol/l has been suggested and good results shown when such levels were achieved in the treatment of serious infections."6 Although a relationship between trough level and toxicity has not been found, rising trough levels give warning of accumulation, and if these are kept below 2 risk. As saliva levels indicate the free (active) fraction of drug in the plasma, they will reflect changes in the effective drug concentration arising from disease processes, varying albumin concentrations, and drug interactions.
Most reports refer to the use of mixed saliva, and this can easily be collected from children of all ages, although saliva flow stimulation using citric acid crystals'24 may sometimes be required. Table 3 shows the relative usefulness of saliva monitoring for the more relevant drugs and lists their respective derived therapeutic ranges. The method is especially useful for carbamazepine, ethosuximide, and phenytoin as there is a good correlation between saliva and plasma levels for each of these drugs,125-127 and this is independent of concurrent drug use, saliva flow rate, or pH. [128] [129] [130] [131] The usefulness of monitoring other drugs in saliva is less clear. Phenobarbitone is partially ionised at the usual saliva pH, and so the S/P ratio varies with saliva pH. However, if the pH is taken into account, a corrected saliva concentration approximating the unbound fraction may be calculated. '32 Although there is a good correlation between saliva and plasma primidone concentrations,'27 monitoring of this drug is limited by the problems associated with phenobarbitone monitoring. The reported plasma digoxin S/P ratios in adults suggest that there is a wide interindividual variation,133 135 This review has attempted to provide a paediatric perspective of drug level monitoring, outlining the indications, considerations, and pitfalls. Some drugs (for example, lignocaine, mexiletine, procainamide, quinidine, disopyramide, lithium, tricyclic antidepressants) have been omitted from discussion as they are rarely used in paediatric practice. Individual treatment, by monitoring drug levels, would seem to be particularly important for children in view of the pronounced interindividual and age-related variation in drug response throughout childhood. However, it should be stressed that such monitoring is no substitute for sound clinical judgment, and comprehensive examination and assessment of children receiving drugs. It is only when optimum and complementary use of both approaches is realised that children will benefit most. 
